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Conversion of laparoscopic colorectal resection (LCR) for cancer has been associated with adverse 
short-term and oncologic outcomes. However, most studies have had small sample sizes and short 
follow-up periods. This study aimed to evaluate the impact of conversion to open surgery on early 
postoperative outcomes and survival among patients undergoing LCR for nonmetastatic colorectal 
cancer. 
Methods 
A prospective database of consecutive LCRs for nonmetastatic colorectal cancer was reviewed. 
Patients who required conversion (CONV group) were compared with those who had completed 
laparoscopic resection (LAP group). Only patients with a minimum 5-year follow-up period were 
included in the oncologic analysis. Kaplan–Meier curves were compared to analyze survival. A 
multivariate analysis was performed to identify predictors of poor survival. 
Results 
The conversion rate was 10.9 %. The most common reason for conversion was a locally advanced 
tumor (48.4 %). Conversion was associated with a significantly longer operative time and a greater 
blood loss. No differences were observed in terms of postoperative morbidity, mortality, or hospital 
stay between the CONV and LAP patients. During a median follow-up period of 120 months 
(range, 60–180 months), the CONV group had a significantly worse 5-year overall survival (OS) 
(79.4 vs 87.4 %; p = 0.016) and disease-free survival (DFS) (65.4 vs 79.6 %; p = 0.013). Univariate 
analysis showed that conversion to open surgery, postoperative complications, anastomotic leakage, 
pT4 cancer, stage 3 disease, and adjuvant chemotherapy were significant risk factors for OS and 
DFS. On multivariate analysis, pT4 cancer and a lymph node ratio (LNR) of 0.25 or greater were 
the only independent predictors of DFS and OS, whereas a LNR of 0.01 to 0.24 showed a trend that 
did not reach statistical significance. 
Conclusion 
Conversion to open surgery per se is not associated with worse early postoperative outcomes and 
does not adversely affect long-term survival per se. 
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Large multicenter randomized clinical trials (RCTs) [1–4] have shown several short-term benefits 
of laparoscopic resection compared with open resection for colon cancer, such as reduced 
intraoperative blood loss, postoperative pain, and morbidity; improved postoperative pulmonary 
function; and shorter duration of postoperative ileus, translating into a shorter hospital stay and 
reduced costs. 
Recent large RCTs [5, 6] as well as a systematic review and metaanalysis of the literature [7] have 
reported similar advantages of laparoscopic rectal resection and total mesorectal excision (TME) 
compared with open surgery for extraperitoneal rectal cancer. 
Evidence from the literature also has shown comparable outcomes in terms of oncologic clearance 
and long-term survival between laparoscopic and open resection for colon [1, 8–10] and rectal 
cancer [10–12]. 
The rates for conversion of laparoscopic colon resection to open surgery reported in the largest 
multicenter RCTs range from 17 to 25 % [2–4], whereas the conversion rates for laparoscopic rectal 
resection vary between 0.6 and 32.4 % [7]. With the exception of the conventional versus 
laparoscopic-associated surgery in colorectal cancer (CLASICC) trial, all RCTs have analyzed 
converted patients in the laparoscopic group on an “intention-to-treat” basis. 
A few nonrandomized studies have examined the short-term outcomes for converted cancer 
patients. Some studies have reported higher morbidity and mortality rates and a longer 
postoperative hospital stay [3, 13–18], whereas others did not find significant differences in 
comparisons with to non converted patients [12, 19–22]. The oncologic outcomes for converted 
patients are poorly investigated, and the data currently available are unclear [10, 12–23]. 
This study aimed to evaluate the impact of conversion to open surgery on short- and long-term 
outcomes in a large series of patients undergoing laparoscopic resection for nonmetastatic colorectal 
cancer. 
Materials and methods 
This study was a retrospective analysis of a prospectively collected database. Consecutive patients 
with colorectal cancer referred for surgical management at our Institution between January 1993 
and December 2012 and treated laparoscopically were identified. 
The exclusion criteria were preoperative diagnosis of liver or lung metastases or peritoneal 
carcinomatosis, invasion of adjacent organs evident preoperatively, acute intestinal obstruction or 
perforation, and history of colorectal surgery. 
All the procedures were performed by two surgeons (M.M., M.D.) who had extensive experience in 
colorectal and laparoscopic advanced surgery using the same oncologic principles in all procedures 
(i.e., adequate margins of resection, en bloc vascular resection and lymphadenectomy, and minimal 
intraoperative manipulation of the tumor). 
During right hemicolectomy, the bowel specimen was extracted through a transverse incision using 
of a wound protector, and an extracorporeal end-to-end hand-sewn or side-to-side stapled 
anastomosis was performed. During left hemicolectomy, sigmoidectomy, and anterior resection, the 
specimen was removed through a small suprapubic transverse incision, and the anastomosis was 
performed by laparoscopic transanal intracorporeal stapled technique. A partial mesorectal excision 
was performed for the treatment of upper rectal cancers, whereas a TME was performed in cases of 
mid-lower rectal cancers. When digital examination showed tumor involvement of the anatomic 
anal canal or tumor fixation to the pelvic floor, a laparoscopic abdominoperineal resection (APR) 
was performed. 
The preoperative workup was standardized for both the colon and rectal cancer patients. The 
evaluation of the colon cancer patients included physical examination, total colonoscopy, 
abdominal computed tomography (CT) scan, chest X-ray, and carcinoembryonic antigen (CEA) 
assay. 
The preoperative staging of rectal cancer included chest and upper abdominal CT scan and transanal 
endoscopic ultrasound. A pelvic CT scan was obtained until 2003, after which all patients 
underwent pelvic magnetic resonance imaging (MRI). 
Neoadjuvant chemoradiotherapy (CRT) for extraperitoneal rectal cancer patients was discussed in a 
multidisciplinary setting. Patients preoperatively staged as T3–T4 N0–N1 without distant 
metastases received preoperative CRT (45 Gy over 4 weeks, together with systemic 5-fluouracil 
intravenous infusion) and were reevaluated with clinical examination, rigid rectoscopy, endoscopic 
ultrasound, and CT or MRI 4 weeks after completion of the CRT. The definitive indication for 
laparoscopic TME was decided at this point, excluding T4 tumors that did not show clinical 
downstaging or downsizing because they were considered a contraindication to the laparoscopic 
approach. 
The pre- and postoperative management was standardized. Preoperative mechanical bowel 
preparation was routinely used until 2005. In all cases, intravenous antibiotic prophylaxis was 
administered before incision. Unless contraindicated, antithrombotic prophylaxis with subcutaneous 
heparin and a sequential compression device was routinely used. Postoperative analgesia was 
achieved by intravenous local anesthetics (such as bupivacaine) for the first 48 h and by 
paracetamol and parenteral nonsteroidal analgesics. Oral intake was allowed the day after the first 
flatus occurred. 
A prospective protocol was designed to evaluate the following parameters: patient’s characteristics 
(age, gender, and American Society of Anesthesiologists [ASA] score), indications for surgery, 
operative variables, pathologic examination, short-term (within 30 days after surgery), and long-
term oncologic outcomes. The operative variables included operative time (from skin incision to the 
application of dressings), intraoperative morbidity, mortality, and rate of conversion to open 
surgery. Conversion to open surgery was defined as an unplanned incision or an incision made 
larger or earlier than planned. The short-term outcomes included resumption of gastrointestinal 
functions, morbidity according to Dindo classification [24], and length of postoperative hospital 
stay. 
Pathologic examination included stage of disease according to the tumor node metastasis (TNM) 
classification [25], length of the surgical specimen, number of lymph nodes harvested, lymph node 
ratio (LNR) (defined as the number of positive nodes divided by the total nodes harvested), and 
resection margins (longitudinal and radial in case of rectal cancer). Lymph nodes in the 
mesocolonic and mesorectal fatty tissue were identified after formalin fixation of the specimen. 
Stage 3 patients were divided into two categories according to LNR (0.01–0.24 and ≥0.25). 
Only patients undergoing laparoscopic colorectal resection (LCR) by 31 December 2007 were 
included in the long-term oncologic analysis. Adjuvant chemotherapy was administered routinely to 
stages 2 and 3 colon cancer patients. Similarly, all rectal cancer patients undergoing neoadjuvant 
CRT and those with a postoperative diagnosis of stage 2 or 3 cancer were offered an adjuvant 
treatment after a clinical oncologic evaluation within 8 weeks after surgery. 
All colon cancer patients were followed up with clinical examination, serum CEA assay every 
3 months, and liver ultrasound every 6 months for the first 2 years, then annually. Chest X-ray and a 
CT scan of the abdomen and pelvis were performed every year. A colonoscopy was performed at 
12 months, then every 3 years. 
The follow-up assessment of rectal cancer patients consisted of digital examination, rectoscopy, and 
CEA assay every 3 months for the first 2 years, then every 6 months. A full colonoscopy was 
performed at 12 months and then every 3 years. A chest CT scan and a CT scan of the abdomen and 
pelvis were obtained at 6 and 12 months, then every year thereafter. 
The long-term oncologic outcomes included the local recurrence rate, the incidence of abdominal 
wall and distant metastases, overall survival (OS), and disease-free survival (DFS). The data were 
collected prospectively from the time the primary malignancy was diagnosed. 
Statistical analysis 
Quantitative data are given as median and range, and categorical data are expressed as percentages. 
Proportions were compared using the chi-square test or Fisher’s exact test, where appropriate. 
Student’s t test was used to compare normally distributed variables. Patients with a minimum 
follow-up period of 60 months were included in the oncologic analysis. 
Univariate analyses of 5-year OS and DFS rates were performed using the Kaplan–Meier method, 
and the differences between the groups were analyzed using the log-rank test. Patients’ observations 
were censored on the date of last examination or death. 
A multivariable Cox regression analysis was performed to identify predictive factors of poor DFS 
and OS using both forward and backward stepwise selection. Explanatory variables with 
univariable p values equal to 0.200 or lower were included in the multivariable analysis. This 
significance level was chosen to incorporate all potentially important predictor variables in the final 
modeling process. The variables analyzed were age, gender, tumor site, conversion to open surgery, 
pT staging, number of harvested lymph nodes, LNR, perioperative blood transfusion, postoperative 
complications, postoperative anastomotic leakage, and adjuvant chemotherapy. The results are 
reported as hazard ratios (HR) with 95 % confidence intervals (CI). A level of 5 % was set as the 
criterion for statistical significance. The data were collected on an Excel spreadsheet. The statistical 
analysis was performed using SYSTAT Version 10 (SPSS Inc., Chicago, IL, USA). 
Results 
Between January 1993 and December 2012, 1,114 patients with nonmetastatic colorectal cancer 
underwent elective LCR. Whereas 992 procedures were completed laparoscopically (LAP group), 
conversion to open surgery was necessary in 122 cases (10.9 %) (CONV group). 
The characteristics of the patients are listed in Table 1. The median age was significantly higher in 
the CONV group than in the LAP group. No differences in gender, body mass index (BMI), ASA 
score, tumor site, or use of neoadjuvant CRT in rectal cancer patients were observed between the 
two groups. 
Table 1  
Baseline patient characteristics 
  CONV (n = 122) LAP (n = 992) p value 
Gender 
 Male n (%) 69 (56.6) 530 (53.4) 0.577 
Age years (range) 
 Median 68 (47–89) 67 (24–92) 0.018 
BMI kg/m2 (range) 
 Median 24 (20–36) 23 (16–47) 0.163 
ASA score n (%) 
1 26 (21.3) 184 (18.5) 0.539 
2 58 (47.5) 452 (45.6) 0.795 
3 37 (30.4) 337 (34) 0.482 
4 1 (0.8) 19 (1.9) 0.618 
Tumor site n (%) 
 Cecum/ascending colon 21 (17.2) 147 (14.8) 0.573 
 Hepatic flexure 4 (3.3) 33 (3.3) 0.810 
 Transverse colon 5 (4.1) 28 (2.8) 0.616 
 Splenic flexure 6 (4.9) 25 (2.5) 0.219 
 Descending colon 8 (6.6) 58 (5.9) 0.912 
 Sigmoid colon 33 (27) 350 (35.3) 0.088 
Rectum 45 (36.9) 351 (35.4) 0.821 
 Upper 14 (31.1) 131 (37.3) 0.516 
 Mid/lower 31 (68.9) 220 (62.7)   
Neoadjuvant CRT n (%) 8(25.8) 66 (30) 0.788 
CONV converted, LAP laparoscopically completed, BMI body mass index, ASA American Society 
of Anesthesiologists, CRT chemoradiation therapy for mid/lower rectal cancer 
Intraoperative results 
The type of procedure performed was similar in the groups, as reported in Table 2. Among the 122 
conversions to open surgery, 59 (48.4 %) were due to a locally advanced cancer, whereas 5 (4.1 %) 
were due to intraoperative complications (Table 2). No differences were observed in terms of 
conversion rate between colon and rectal resections (10.7 vs 11.4 %; p = 0.821). The conversion 
rate did not change significantly over time, as shown in Fig. 1. 
Table 2  
Perioperative results 
  CONV (n = 122) LAP (n = 992) p value 
Procedure n (%) 
 Right hemicolectomy 27 (22.1) 204 (20.6) 0.776 
 Left hemicolectomy 27 (22.1) 193 (19.4) 0.562 
 Sigmoidectomy 20 (16.4) 196 (19.8) 0.444 
 Anterior resection 36 (29.5) 337 (34) 0.377 
 APR 9 (7.4) 55 (5.5) 0.539 
 Hartmann 3 (2.5) 7 (0.7) 0.153 
Median operative time min (range) 
 Overall 180 (90–420) 140 (45–360) <0.001 
 Colon 150 (90–330) 125 (45–300) <0.001 
 Rectum 200 (130–420) 175 (60–360) <0.001 
Median intraoperative blood loss ml (range) 
 Overall 150 (25–1000) 100 (10–2800) <0.001 
 Colon 100 (25–1000) 70 (10–600) <0.001 
 Rectum 150 (50–1000) 100 (10–2800) <0.001 
Reasons for conversion n (%) 
 Tumor related (locally advanced tumor) 
  Overall 59 (48.4)     
  Colon 44 (57.1)     
  Rectum 15 (33.3)     
 Non–tumor related 
  Overall 63 (51.6)     
  Colon 33 (42.9)     
  Rectum 30 (66.7)     
   Obesity 23 (18.8)     
   Adhesions 18 (14.8)     
   Subocclusion 11 (9)     
   Unclear anatomy 6 (4.9)     
   Intraoperative complications 5 (4.1)     
    Hypercapnia 2     
    Bleeding 2     
    Visceral injury 1     
Postoperative complications n (%) 
 Overall 20 (16.4) 156 (15.7) 0.849 
 Colon 10 (12.9) 93 (14.5) 0.864 
 Rectum 10 (22.2) 63 (17.9) 0.539 
 Grade 1 3 (2.5) 21 (2.1) 0.806 
 Grade 2 11 (9.0) 66 (6.7) 0.332 
 Grade 3 5 (4.1) 63 (6.3) 0.327 
 Grade 3a 1 (0.8) 12 (1.2) 0.705 
 Grade 3b 4 (3.3) 51 (5.1) 0.370 
 Grade 4 0 3 (0.3) 0.543 
 Grade 5 1 (0.8) 3 (0.3) 0.367 







Fig. 1  
 
Conversion, locally advanced cancer, and rectal cancer rates over time. LCR laparoscopic colorectal 
resection 
Overall, the median operative time decreased significantly after the first 100 cases, from 180 min 
(range, 70–360 min) to 150 min (range, 85–330 min) (p = 0.049). We then observed a slow and 
progressive further reduction in the median operative time to 125 min (range, 45–360 min) in the 
last 100 cases. The median operative time was 180 min (range, 90–420 min) in the CONV group 
and 140 min (range, 45–360 min) in the LAP group (p < 0.001). The median estimated blood loss 
was 150 ml (range, 25–1,000 ml) in the CONV group and 100 ml (range, 10–2,800 ml) in the LAP 
group (p < 0.001). 
An en bloc multivisceral resection was necessary for five (4.1 %) CONV patients (2 ileal resections, 
2 partial cystectomies, and 1 abdominal wall resection) and for 5 (0.5 %) LAP patients (2 ileal 
resections, 2 distal splenopancreatectomies, and 1 vaginal posterior wall resection). 
Short-term postoperative results 
Return of bowel function occurred 1 day later in the CONV colon cancer group than in LAP colon 
cancer group (5 vs 4 days; p < 0.001), whereas no differences between the CONV and LAP rectal 
cancer patients were observed (4 days in both groups; p = 0.228). 
A significantly higher rate of perioperative blood transfusions was observed in the CONV group 
(7.4 vs 3.6 %; p = 0.047), with no significant differences between the colon and rectal cancer 
patients (7.8 % of CONV colon cancer patients vs 6.6 % of CONV rectal cancer patients; 
p = 0.981). 
No differences were observed in terms of overall 30-day postoperative morbidity rate between the 
CONV and LAP groups (16.4 vs 15.7 %; p = 0.849) regardless of the tumor location (colon vs 
rectum). In particular, no statistically significant differences were observed between the groups in 
terms of rates for wound infection (2.5 vs 0.9 %; p = 0.117), cardiopulmonary complications (0.8 vs 
2.3 %; p = 0.282), anastomotic leakage (3.3 vs 4.9 %; p = 0.416), reoperation (3.3 vs 5.1 %; 
p = 0.370), or mortality (0.8 vs 0.3 %; p = 0.367) (Table 2). 
The median postoperative hospital stay was longer in the CONV group than in the LAP group (9 vs 
7 days), although the difference did not reach statistical significance (p = 0.120). This trend was 
observed for both colon cancer (8 vs 7 days; p = 0.303) and rectal cancer (10 vs 8 days; p = 0.337) 
patients. 
Pathologic results 
Length of the specimen, number of harvested lymph nodes, and positive margin rates did not differ 
between the two groups (Table 3). No tumor was detected macroscopically at the specimen 
margins. Tumor cells were microscopically found at the specimen margin (R1 resection) in one 
CONV case (0.8 %) and in five LAP cases (0.5 %) (p = 0.837). 
 
Table 3  
 
Pathologic findings 
  CONV (n = 122) LAP (n = 992) p value 
Median specimen length cm (range) 
 Overall 30 (6–50) 28 (6–55) 0.160 
 Colon 31 (6–50) 29 (6–50) 0.195 
 Rectum 28 (15–50) 28 (8–55) 0.157 
Positive margins n (%) 
 Overall 1 (0.8) 5 (0.5) 0.837 
 Colon 0 0 1 
 Rectum 1 (2.2) 5 (1.4) 0.518 
Lymph nodes resected median n (range) 
 Overall 14 (6–47) 13 (5–69) 0.179 
 Colon 15 (6–47) 14 (5–39) 0.188 
 Rectum 14 (5–33) 12 (5–69) 0.135 
T 
 0 0 9 (0.9) 0.603 
 1 9 (7.4) 345 (34.8) <0.001 
 2 13 (10.6) 155 (15.6) 0.189 
 3 85 (69.7) 446 (45) <0.001 
 4 15 (12.3) 37 (3.7) <0.001 
N 
 0 67 (54.9) 679 (68.4) 0.004 
 1 41 (33.6) 174 (17.6) <0.001 
 2 14 (11.5) 139 (14) 0.529 
TNM stage n (%) 
 pCR       
 Overall 0 9 (0.9) 0.603 
 Colon 0 0 1 
 Rectum 0 9 (2.6) 0.606 
1 
 Overall 18 (14.7) 337 (33.9) <0.001 
 Colon 10 (12.9) 206 (32.1) <0.001 
 Rectum 8 (17.8) 131 (37.3) 0.012 
2 
Overall 49 (40.2) 333 (33.6) 0.178 
Colon 38 (49.4) 225 (35.1) 0.017 
Rectum 11 (24.4) 108 (30.8) 0.490 
3       
 Overall 55 (45.1) 313 (31.6) 0.004 
 Colon 29 (37.7) 210 (32.8) 0.443 
 Rectum 26 (57.8) 103 (29.3) <0.001 
CONV converted, LAP laparoscopically completed, TNM tumor node metastasis, pCR pathologic complete response 
Significantly lower rates of pT1 (7.4 vs 34.8 %; p < 0.001) and higher rates of pT3 (69.7 vs 45 %; 
p < 0.001), pT4 (12.3 vs 3.7 %; p < 0.001), and pN1 (33.6 vs 17.6 %; p < 0.001) carcinomas were 
reported in the CONV group than in the LAP group. The pT4 cancers included five pT4b (33.3 %) 
in the CONV group and four pT4b (10.8 %) in the LAP group (p = 0.100). Overall, stage 3 tumors 
were more frequently observed among the CONV patients (45.1 vs 31.6 %; p = 0.004). 
Long-term oncologic results 
Between January 1993 and December 2007, 600 patients underwent LCR for nonmetastatic cancer 
and were considered for oncologic analysis. During a median follow-up period of 120 months 
(range, 60–180 months), 75 patients (12.5 %) were lost to follow-up evaluation. As a result, 525 
patients (53 CONV patients and 472 LAP patients) were included in the analysis. 
A total of 25 CONV patients (47.2 %) and 161 LAP patients (34.1 %) had rectal cancer (p = 0.083). 
The distribution of tumor stages in the two groups of patients was as follows: stage 1 (13.2 %, n = 7 
vs 33.7 %, n = 159; p = 0.004), stage 2 (37.7 %, n = 20 vs 33.3 %, n = 157; p = 0.617), and stage 3 
(49.1 %, n = 26 vs 33 %, n = 156; p = 0.030). The longitudinal and radial margins were clear in all 
cases. A total of 30 CONV patients (56.6 %) and 251 LAP patients (53.2 %) received adjuvant 
chemotherapy (p = 0.742). 
Tumor recurrence occurred more frequently in the CONV group (33.9 vs 21.2 %; p = 0.035). The 
local recurrence rate was 11.3 % in the CONV group (6 patients) and 5.1 % in the LAP group (24 
patients) (p = 0.064). Distant metastases developed in 12 CONV patients (22.6 %) and in 76 LAP 
patients (16.1 %, 1 case of port-site metastasis) (p = 0.244). Combined local and distal recurrence 
was observed in five LAP patients (1.1 %; p = 0.994). 
The median time until recurrence did not differ between the two groups (17 months; range, 3–
107 months in the CONV group and 20 months; range, 2–108 months in the LAP group; p = 0.374). 
Both the 5-year OS and DFS rates were significantly lower for the CONV patients (79.4 vs 87.4 %; 
p = 0.016; Fig. 2A) than for the LAP patients (65.4 vs 79.6 %; p = 0.013; Fig. 2B). No significant 
differences were observed in a stage-by-stage comparison between the two groups (Table 4). 
 
Fig. 2  
Long-term oncologic outcomes. A Overall survival (p = 0.016, log-rank test). B Disease-free 
survival (p = 0.013, log-rank test). LAP laparoscopically completed, CONV converted 
Table 4  
Oncologic outcomes 
  CONV (n = 53) (%) LAP (n = 472) (%) p value 
5-Year overall survival 79.4 87.4 0.016 
 Stage 1 100 98.6 0.615 
 Stage 2 81.3 93 0.112 
 Stage 3 65.8 70 0.264 
5-Year disease-free survival 65.4 79.6 0.013 
 Stage 1 100 94.2 0.462 
 Stage 2 74.4 84.7 0.251 
 Stage 3 49.3 59.3 0.188 
CONV converted, LAP laparoscopically completed 
The univariate analysis found conversion to open surgery, postoperative complications, anastomotic 
leakage, pT4 cancer, stage 3 disease (LNR ≥0.01), and adjuvant chemotherapy to be significant risk 
factors for OS and DFS (Tables 5 and 6). In particular, both the 5-year OS and 5-year DFS were 
significantly higher for the T1–T3 patients (88.2 vs 51.9 %; p < 0.001) than for the pT4 patients (80 
vs 38.1 %; p < 0.001), and for the stages 1 and 2 patients (95.6 vs 69.3 %; p < 0.001) than for the 
stage 3 patients (88.8 vs 57.9 %; p < 0.001). 
 
Table 5  
Univariate and multivariate analysis of risk factors for overall survival 
  n = 525 
Univariate analysis Multivariate analysis 
Hazard ratio (95 % CI) p valuea Hazard ratio (95 % CI) p valuea 
Median age (years) 
 >66 256 1       
 ≤66 269 1.22 (0.75–1.99) 0.428     
Gender 
 Female 235 1       
 Male 290 0.99 (0.61–1.63) 0.992     
Tumor site 
 Colon 339 1   1   
 Rectum 186 1.39 (0.85–2.29) 0.185 1.21 (0.64–2.28) 0.559 
Conversion to open surgery 
 No 472 1   1   
 Yes 53 2.07 (1.05–4.08) 0.033 1.01 (0.40–2.49) 0.989 
pT staging 
 T1–T3 504 1   1   
 T4 21 6.18 (2.49–15.29) <0.001 7.79 (2.47–1.61) <0.001 
No. of harvested lymph nodes 
 ≥12 291 1       
 <12 234 1.09 (0.67–1.77) 0.738     
Lymph node ratio 
 0 343 1   1   
 0.01–0.24 107 1.62 (0.93–2.83) 0.086 1.46 (0.81–2.52) 0.109 
 ≥0.25 75 8.34 (4.77–14.59) <0.001 10.03 (4.66–21.59) <0.001 
Perioperative blood transfusion 
 No 500 1       
 Yes 25 1.48 (0.54–4.08) 0.443     
  n = 525 
Univariate analysis Multivariate analysis 
Hazard ratio (95 % CI) p valuea Hazard ratio (95 % CI) p valuea 
Postoperative complications 
 No 449 1   1   
 Yes 76 1.94 (1.06–3.56) 0.030 1.45 (0.59–3.53) 0.410 
Postoperative anastomotic leakage 
 No 503 1   1   
 Yes 22 2.28 (0.86–6.02) 0.089 1.62 (0.43–6.01) 0.474 
Adjuvant CT 
 No 244 1   1   
 Yes 281 3.95 (2.21–7.06) <0.001 1.59 (0.79–3.24) 0.194 
CI confidence interval, CT chemotherapy 
aStepwise logistic regression analysis 
 
 
Table 6  
Univariate and multivariate analysis of risk factors for disease-free survival 
  n = 525 
Univariate analysis Multivariate analysis 
Hazard ratio (95 % CI) p valuea Hazard ratio (95 % CI) p valuea 
Median age (years) 
 >66 256 1   1   
 ≤66 269 1.33 (0.88–2.02) 0.171 1.06 (0.63–1.81) 0.815 
Gender 
 Female 235 1       
 Male 290 1.04 (0.69–1.57) 0.863     
Tumor site 
 Colon 339 1   1   
 Rectum 186 1.47 (0.96–2.23) 0.073 1.22 (0.71–2.09) 0.463 
Conversion to open surgery 
 No 472 1   1   
 Yes 53 1.91 (1.04–3.52) 0.035 1.14 (0.51–2.51) 0.753 
pT staging 
 T1–T3 504 1   1   
 T4 21 7.29 (2.98–17.85) <0.001 5.18 (1.65–16.28) 0.005 
No. of harvested lymph nodes 
 ≥12 291 1       
 <12 234 1.11 (0.74–1.68) 0.613     
Lymph node ratio 
 0 343 1   1   
 0.01–0.24 107 1.75 (1.09–2.81) 0.027 1.86 (0.98–3.98) 0.059 
 ≥0.25 75 7.21 (4.28–12.17) <0.001 8.29 (4.23–16.29) <0.001 
Perioperative blood transfusion 
 No 500 1       
  n = 525 
Univariate analysis Multivariate analysis 
Hazard ratio (95 % CI) p valuea Hazard ratio (95 % CI) p valuea 
 Yes 25 1.36 (0.56–3–35) 0.498     
Postoperative Complications 
 No 449 1   1   
 Yes 76 1.62 (0.94–2.77) 0.079 1.05 (0.46–2–37) 0.909 
Postoperative anastomotic leakage 
 No 503 1   1   
 Yes 22 2.50 (1.04–6.01) 0.034 1.95 (0.57–6.65) 0.285 
Adjuvant CT 
 No 244 1   1   
 Yes 281 3.88 (2.39–6.29) <0.001 1.48 (0.85–2.92) 0.191 
CI confidence interval, CT chemotherapy 
aStepwise logistic regression analysis 
In the multivariate analysis, pT4 cancer and a LNR of 0.25 or more were the only independent 
predictors of OS and DFS, whereas a LNR of 0.01 to 0.24 showed a trend that did not reach 
statistical significance (Tables 5 and 6). 
Discussion 
The feasibility and safety of LCR for cancer has been demonstrated in several RCTs [1–4]. 
However, LCR is a technically demanding procedure that involves bowel mobilization in multiple 
abdominal quadrants, dissection and ligation of large vessels, and restoration of the intestinal 
continuity with an anastomosis. 
Many variables associated with conversion to open surgery have been described. These variables 
include patient-specific factors such as high BMI, older age, and high ASA score; disease-specific 
factors such as T4 cancers; and procedure-specific factors such as rectal versus colon resection and 
the surgeon’s experience [4, 26]. 
We reported a 10.9 % conversion rate in this series of 1,114 patients undergoing LCR for 
nonmetastatic colorectal cancer. No differences were noted in terms of conversion rates between the 
colon and rectal cancer patients (10.7 vs 11.4 %). We found that a locally advanced tumor was the 
most common reason for conversion to open surgery (57.1 % among the colon cancer patients and 
33.3 % among the rectal cancer patients), followed by obesity (18.8 %) and adhesions (14.8 %), 
confirming the data previously reported in the CLASICC trial [3]. 
Currently, we consider a preoperatively suspected T4 colorectal cancer to be a contraindication to 
LCR. However, 52 patients in our series had a postoperative diagnosis of a pT4 cancer (9 pT4b), 
reflecting that CT scan sensitivity for the preoperative diagnosis of T4 colorectal cancer is 
suboptimal [27]. 
Some studies have investigated the learning curve in LCR [3, 14, 28–33], observing the trend in 
operative time and conversion rate according to the surgeon’s experience. For instance, Marusch et 
al. [29] showed a significantly lower conversion rate for surgeons with experience of more than 100 
LCRs than for surgeons who had performed fewer than 100 such procedures. In contrast, other 
studies [34] and the current series did not observe significant differences in terms of conversion rate 
according to the surgeon’s experience. 
To the best of our knowledge, this study involved the largest series of patients undergoing LCR for 
nonmetastatic colorectal cancer. We demonstrated a significant decrease in the operative time after 
the first 100 cases, but no significant differences were observed over time in terms of conversion 
rate. This may be related to the fact that in our experience, the learning curve is reflected in the 
operative time required to complete the procedure, whereas the selection criteria for LCR did not 
change during the study period (Fig. 1). 
Several studies have investigated the impact that conversion of LCR has on perioperative outcomes. 
The intraoperative results in our series are consistent with those reported in the literature, with 
conversion to open surgery leading to a significantly longer operative time and increased blood loss 
[3, 13–18]. 
Regarding postoperative short-term outcomes, significantly higher morbidity and mortality rates 
and a prolonged hospital stay are widely reported after conversion of LCR [14, 18, 29, 35, 36]. 
However, the interpretation of these results is limited by the small and heterogeneous groups of 
patients considered because many studies have included benign diseases such as diverticulitis and 
inflammatory bowel disease besides colorectal cancers. Data restricted to cancer patients are more 
controversial [3, 17, 19, 20, 22]. Whereas some authors [3, 17] have observed that patients 
undergoing conversion had significantly higher rates of blood transfusions, surgical complications 
including anastomotic leakage, and reintervention than patients who had a completed LCR, others 
did not find adverse effects of conversion on the early postoperative outcomes for patients with 
colorectal cancer. 
Franko et al. [19] compared 31 patients undergoing converted LCR with 143 patients undergoing 
completed LCR. The rates for postoperative morbidity including wound infection, prolonged ileus 
and anastomotic leaks, in-hospital mortality, and readmission were similar in the two groups. 
Similar results were reported by Ptok et al. [20] <C>, who did not observe significant differences in 
terms of morbidity and mortality rates between 56 patients who had conversion and 290 patients 
who had completed LCR. 
In our series, we observed a significantly higher rate of perioperative blood transfusions in the 
CONV group patient than in the LAP group (7.4 vs 3.6 %; p = 0.047), with no significant difference 
between the colon and rectal cancer patients (7.8 % of the CONV colon cancer patients vs 6.6 % of 
the CONV rectal cancer patients). However, there were no statistically significant differences 
between the CONV and LAP groups in terms of overall postoperative morbidity (16.4 vs 15.7 %) 
regardless of tumor location, wound infections (2.5 vs 0.9 %), cardiopulmonary complications (0.8 
vs 2.3 %), or mortality (0.8 vs 0.3 %). The hospital stay was prolonged in the CONV group (colon 
cancer patients: 8 vs 7 days; rectal cancer patients: 10 vs 8 days), consistent with the results 
reported in the literature, although these differences did not reach statistical significance. 
In nonrandomized comparative and descriptive studies, conversion also is associated with worse 
oncologic outcomes in terms of higher local recurrence and reduced survival rates [13, 16, 18, 20, 
21, 23]. However, the cited studies present several shortcomings including small sample sizes, short 
follow-up periods, and lack of adequate statistical analysis that limit the interpretation of the results. 
To the best of our knowledge, the CLASICC trial is the only RCT that has reported long-term 
oncologic outcomes for converted patients, whereas all other RCTs have analyzed converted 
patients in the laparoscopic group on an “intention-to-treat” basis. 
Green et al. [10] recently found that converted colon cancer patients had significantly worse OS and 
DFS, even after adjustment for stratification factors, age, sex, and TNM stage, during a median 
follow-up period of 62.9 months than patients undergoing open surgery, suggesting that the disease 
itself adversely affects survival rather than conversion per se. 
We analyzed 525 (53 converted) patients with a median follow-up period of 120 months after LCR. 
The median time until recurrence did not differ between the two groups: 17 months (range, 3–
107 months) in the CONV group and 20 months (range, 2–108 months) in the LAP group 
(p = 0.374). Both OS and DFS were significantly lower for the converted patients. However, in the 
multivariate analysis, pT4 cancer and a LNR of 0.25 or more were the only independent predictors 
for DFS and OS, whereas a LNR of 0.01–0.24 showed a trend that did not reach statistical 
significance. In particular, both 5-year OS and 5-year DFS were significantly poorer for pT4 
patients (51.9 vs 88.2 %; p < 0.001) than for pT1–pT3 patients (38.1 vs 80 %; p < 0.001). 
We believe that the good results reported in our series of CONV patients are associated with our 
attitude of considering early conversion for locally advanced colorectal malignancies. This surgical 
strategy avoids excessive tumor handling or incorrect oncologic dissection by the laparoscopic 
approach, thus reducing the risk of tumor cell spillage and potentially adverse oncologic outcomes. 
Recently, some retrospective studies have specifically investigated oncologic outcomes in T4 
colorectal cancer patients after laparoscopic resection [37–39], concluding that a laparoscopic 
approach to T4 colorectal cancer is safe and does not affect oncologic outcomes compared with the 
open approach. However, RCTs are needed to confirm these suggestions. 
In conclusion, despite the limitations of a retrospective study, the results of this large series show 
that locally advanced cancer is the first reason for conversion to open surgery and that a pT4 cancer 
is independently associated with poor survival. Conversion per se does not adversely affect short-
term outcomes or long-term survival in patients with nonmetastatic colorectal cancer. 
Acknowledgments 





Lacy AM, García-Valdecasas JC, Delgado S, Castells A, Taurá P, Piqué JM, Visa J (2002) 
Laparoscopy-assisted colectomy versus open colectomy for treatment of nonmetastatic colon 
cancer: a randomised trial. Lancet 359:2224–2229 
2. 
Clinical outcomes of Surgical Therapy Study Group (2004) A comparison of laparoscopically 
assisted and open colectomy for colon cancer. N Engl J Med 350:2050–2059 
3. 
Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM, MRC 
CLASICC trial group (2005) Short-term end points of conventional versus laparoscopic-assisted 
surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised 
controlled trial. Lancet 365:1718–1726 
4. 
Veldkamp R, Kuhry E, Hop WC, Jeekel J, Kazemier G, Bonjer HJ, Haglind E, Påhlman L, Cuesta 
MA, Msika S, Morino M, Lacy AM, COlon cancer Laparoscopic or Open Resection Study Group 
(COLOR) (2005) Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes 
of a randomised trial. Lancet Oncol 6:477–484 
5. 
Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, 
Chang HJ, Lee HS, Kim SY, Jung KH, Hong YS, Kim JH, Sohn DK, Kim DH, Oh JH (2010) Open 
versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy 
(COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol 
11:637–645 
6. 
van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, Bonjer HJ, COlorectal 
cancer Laparoscopic or Open Resection II (COLOR II) Study Group (2013) Laparoscopic versus 
open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. 
Lancet Oncol 14:210–218 
7. 
Arezzo A, Passera R, Scozzari G, Verra M, Morino M (2013) Laparoscopy for rectal cancer reduces 





Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr, Hellinger M, Flanagan R Jr, 
Peters W, Nelson H, Clinical Outcomes of Surgical Therapy Study Group (2007) Laparoscopic 
colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study 
Group trial. Ann Surg 246:655–662 discussion 662–664 
9. 
Colon Cancer Laparoscopic or Open Resection Study Group, Buunen M, Veldkamp R, Hop WC, 
Kuhry E, Jeekel J, Haglind E, Påhlman L, Cuesta MA, Msika S, Morino M, Lacy A, Bonjer HJ 
(2009) Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome 
of a randomised clinical trial. Lancet Oncol 10:44–52 
10. 
Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, Brown JM (2013) Long-term 
follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically 
assisted resection in colorectal cancer. Br J Surg 100:75–82 
11. 
Anderson C, Uman G, Pigazzi A (2008) Oncologic outcomes of laparoscopic surgery for rectal 
cancer: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 34:1135–1142 
12. 
Laurent C, Leblanc F, Wütrich P, Scheffler M, Rullier E (2009) Laparoscopic versus open surgery 
for rectal cancer: long-term oncologic results. Ann Surg 250:54–61 
13. 
Chan AC, Poon JT, Fan JK, Lo SH, Law WL (2008) Impact of conversion on the long-term 
outcome in laparoscopic resection of colorectal cancer. Surg Endosc 22:2625–2630 
14. 
Agha A, Fürst A, Iesalnieks I, Fichtner-Feigl S, Ghali N, Krenz D, Anthuber M, Jauch KW, Piso P, 
Schlitt HJ (2008) Conversion rate in 300 laparoscopic rectal resections and its influence on 
morbidity and oncological outcome. Int J Colorectal Dis 23:409–417 
15. 
Yamamoto S, Fukunaga M, Miyajima N, Okuda J, Konishi F, Watanabe M, Japan Society of 
Laparoscopic Colorectal Surgery (2009) Impact of conversion on surgical outcomes after 
laparoscopic operation for rectal carcinoma: a retrospective study of 1,073 patients. J Am Coll Surg 
208:383–389 
16. 
Li JC, Lee JF, Ng SS, Yiu RY, Hon SS, Leung WW, Leung KL (2010) Conversion in laparoscopic-
assisted colectomy for right colon cancer: risk factors and clinical outcomes. Int J Colorectal Dis 
25:983–988 
17. 
Scheidbach H, Garlipp B, Oberländer H, Adolf D, Köckerling F, Lippert H (2011) Conversion in 
laparoscopic colorectal cancer surgery: impact on short- and long-term outcome. J Laparoendosc 
Adv Surg Tech A 21:923–927 
18. 
White I, Greenberg R, Itah R, Inbar R, Schneebaum S, Avital S (2011) Impact of conversion on 
short- and long-term outcome in laparoscopic resection of curable colorectal cancer. JSLS 15:182–
187 
19. 
Franko J, Fassler SA, Rezvani M, O’Connell BG, Harper SG, Nejman JH, Zebley DM (2008) 






Ptok H, Kube R, Schmidt U, Köckerling F, Gastinger I, Lippert H, Colon/Rectum Carcinoma 
(Primary Tumor) Study Group (2009) Conversion from laparoscopic to open colonic cancer 
resection-associated factors and their influence on long-term oncological outcome. Eur J Surg 
Oncol 35:1273–1279 
21. 
Rottoli M, Bona S, Rosati R, Elmore U, Bianchi PP, Spinelli A, Bartolucci C, Montorsi M (2009) 
Laparoscopic rectal resection for cancer: effects of conversion on short-term outcome and survival. 
Ann Surg Oncol 16:1279–1286 
22. 
Rottoli M, Stocchi L, Geisler DP, Kiran RP (2012) Laparoscopic colorectal resection for cancer: 
effects of conversion on long-term oncologic outcomes. Surg Endosc 26:1971–1976 
23. 
Moloo H, Mamazza J, Poulin EC, Burpee SE, Bendavid Y, Klein L, Gregoire R, Schlachta CM 
(2004) Laparoscopic resections for colorectal cancer: does conversion affect survival? Surg Endosc 
18:732–735 
24. 
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new 
proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 240:205–
213 
25. 
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the 
AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474 
26. 
Thorpe H, Jayne DG, Guillou PJ, Quirke P, Copeland J, Brown JM; Medical Research Council 
Conventional versus Laparoscopic-Assisted Surgery In Colorectal Cancer Trial Group (2008) 
Patient factors influencing conversion from laparoscopically assisted to open surgery for colorectal 
cancer. Br J Surg 95:199–205 
27. 
Grossmann I, Klaase JM, Avenarius JK, de Hingh IH, Mastboom WJ, Wiggers T (2011) The 
strengths and limitations of routine staging before treatment with abdominal CT in colorectal 
cancer. BMC Cancer 11:433 
28. 
Bennett CL, Stryker SJ, Ferreira MR, Adams J, Beart RW Jr (1997) The learning curve for 
laparoscopic colorectal surgery: preliminary results from a prospective analysis of 1,194 
laparoscopic-assisted colectomies. Arch Surg 132:41–44 discussion 45 
29. 
Marusch F, Gastinger I, Schneider C, Scheidbach H, Konradt J, Bruch HP, Köhler L, Bärlehner E, 
Köckerling F, Laparoscopic Colorectal Surgery Study Group (LCSSG) (2001) Importance of 
conversion for results obtained with laparoscopic colorectal surgery. Dis Colon Rectum 44:207–214 
discussion 214–216 
30. 
Schlachta CM, Mamazza J, Seshadri PA, Cadeddu M, Gregoire R, Poulin EC (2001) Defining a 
learning curve for laparoscopic colorectal resections. Dis Colon Rectum 44:217–222 
31. 
Tekkis PP, Senagore AJ, Delaney CP, Fazio VW (2005) Evaluation of the learning curve in 
laparoscopic colorectal surgery: comparison of right-sided and left-sided resections. Ann Surg 
242:83–91 
32. 
Park IJ, Choi GS, Lim KH, Kang BM, Jun SH (2009) Multidimensional analysis of the learning 
curve for laparoscopic resection in rectal cancer. J Gastrointest Surg 13:275–281 
33. 
Ito M, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y, Saito N (2009) Influence of learning 
curve on short-term results after laparoscopic resection for rectal cancer. Surg Endosc 23:403–408 
34. 
Schwandner O, Schiedeck TH, Bruch H (1999) The role of conversion in laparoscopic colorectal 
surgery: do predictive factors exist? Surg Endosc 13:151–156 
35. 
Belizon A, Sardinha CT, Sher ME (2006) Converted laparoscopic colectomy: what are the 
consequences? Surg Endosc 20:947–951 
36. 
Chew MH, Ng KH, Fook-Chong MC, Eu KW (2011) Redefining conversion in laparoscopic 
colectomy and its influence on outcomes: analysis of 418 cases from a single institution. World J 
Surg 35:178–185 
37. 
Bretagnol F, Dedieu A, Zappa M, Guedj N, Ferron M, Panis Y (2011) T4 colorectal cancer: is 
laparoscopic resection contraindicated? Colorectal Dis 13:138–143 
38. 
Ng DC, Co CS, Cheung HY, Chung CC, Li MK (2011) The outcome of laparoscopic colorectal 
resection in T4 cancer. Colorectal Dis 13:e349–e352 
39. 
Vignali A, Ghirardelli L, Di Palo S, Orsenigo E, Staudacher C (2013) Laparoscopic treatment of 
advanced colonic cancer: a case-matched control with open surgery. Colorectal Dis. doi: 10.1111/
codi.12170  
 
